YOLFTbeta
22

PanGen Biotech Inc

222110 · KQ · Healthcare / Biotechnology

4,005.00KRW+10.00 (+0.25%)

Price History

Full chart

Market Stats

Previous Close3,995.00
Open4,000.00
Day Range3,965.00 – 4,050.00
52-Week Range4,220.00 – 8,510.00
Volume1.72K
Market Cap65.21B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.12
50-Day Avg4,887.50
200-Day Avg5,194.50

About

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jaeseung Yoon
  • Employees0
  • HeadquartersInnoplex 2-dong, Suwon-si, South Korea, 16675, Korea
  • Websitehttps://www.pangen.com

Leadership

  • Dr. Jaeseung YoonPresident & CEO · b. 1961

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.40B3.73B1.46B2.37B5.68B2.88B6.19B7.94B6.50B7.32B14.67B13.42B
Growth (%)-+9.72%-60.83%+62.36%+139.36%-49.27%+114.87%+28.18%-18.08%+12.53%+100.58%-8.56%
Cost of Revenue3.42B3.15B3.70B3.85B5.16B4.98B4.82B7.41B5.84B6.33B9.52B8.91B
Gross Profit-18.55M581.17M-2.24B-1.47B517.57M-2.10B1.37B530.21M659.96M986.29M5.15B4.51B
Gross Margin-0.55%15.58%-153.08%-62.13%9.11%-72.79%22.18%6.68%10.15%13.48%35.10%33.61%
Operating Expense2.00B2.60B5.03B3.68B3.56B6.47B5.07B3.82B5.25B5.21B4.10B3.00B
Operating Income-2.02B-2.02B-7.27B-5.15B-3.04B-8.57B-3.70B-3.29B-4.59B-4.23B1.05B1.51B
Operating Margin-59.42%-54.21%-497.49%-217.25%-53.59%-297.36%-59.75%-41.44%-70.62%-57.76%7.13%11.23%
EBITDA---------2.70B-2.62B2.79B3.68B
EBITDA Margin---------41.58%-35.87%19.04%27.42%
Net Income-2.12B-2.64B-5.13B-7.02B-4.63B-8.94B-4.36B-3.31B-4.49B-4.49B943.69M2.05B
Net Income Margin-62.35%-70.70%-350.69%-295.67%-81.52%-310.19%-70.36%-41.71%-69.13%-61.36%6.43%15.28%
R&D1.30B1.84B4.22B1.65B2.58B4.52B3.68B2.73B3.85B3.33B2.01B1.38B
R&D as % of Total Revenue38.09%49.27%288.50%69.48%45.42%156.96%59.37%34.45%59.22%45.55%13.71%10.30%
Interest Expense0000001.01B293.25M128.77M220.68M322.10M145.87M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%16.36%3.70%1.98%3.02%2.20%1.09%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets16.87B15.90B37.40B35.59B45.61B39.08B36.31B43.28B20.67B20.74B30.54B32.70B
Total Liabilities6.18B9.34B2.09B4.28B18.67B20.66B22.10B22.18B3.45B8.18B5.64B2.78B
Total Equity8.21B6.56B35.31B31.31B26.94B18.43B14.21B21.10B17.22B12.57B24.91B29.92B
Cash2.46B926.15M13.57B8.78B6.93B4.36B8.14B1.19M838.28M343.00K1.12M3.76B
Net Debt-----13.02B10.26B9.79B-1.97B--

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.34B-1.61B-4.35B-657.84M-5.61B-3.66B-4.68B-3.32B-3.50B-3.45B2.99B189.81M
Investing Cash Flow-3.13B-640.30M-9.08B-7.01B-14.42B1.10B8.42B-6.03B14.23B-571.13M-10.34B-
Financing Cash Flow6.43B705.71M26.06B2.89B18.17B-3.51K77.31M10.11B-18.74B3.17B8.73B-
Capital Expenditure548.00M1.58B3.46B2.10B1.06B819.08M755.64M1.43B728.05M484.98M374.12M737.42M
Free Cash Flow------5.91B-5.45B-4.80B-4.24B-3.94B2.61B-547.61M
FCF to OCF-----161.32%116.50%144.36%120.95%114.06%87.47%-288.50%

Earnings

Report DateMar 31, 2016Aug 12, 2016Nov 11, 2016Feb 8, 2017May 12, 2017Aug 11, 2017Nov 10, 2017Feb 14, 2018May 11, 2018Aug 10, 2018Nov 7, 2018Feb 10, 2019May 14, 2019Aug 14, 2019Nov 13, 2019Jan 22, 2020May 12, 2020Aug 13, 2020Nov 13, 2020Feb 1, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------
EPS Actual-239.59-90.10-217.11-89.06-114.70-85.39-71.18-466.25-145.9617.98-17.79-334.80-171.96-218.56-181.04-355.40-126.90-72.00-158.00-94.52-217.38-4.38-38.66-71.07-84.35-206.76-93.10-36.68-121.07-13.57-93.35-192.416.2317.57104.10-39.6857.0863.8936.96-7.5755.62-3.57
Surprise------------------------------------------
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-market----------------------

Key Statistics & Ratios

Market Cap65.21B
Enterprise Value52.89B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.60
Price / Book2.11
Revenue (TTM)14.18B
Gross Profit (TTM)3.99B
EBITDA1.77B
Profit Margin7.99%
Operating Margin-5.55%
Return on Equity3.76%
Return on Assets0.42%
Shares Outstanding13.51M
Shares Float6.39M
Beta-0.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%